Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal

Author:

Allsop DJ12,Lintzeris N23,Copeland J4,Dunlop A56,McGregor IS1

Affiliation:

1. Psychopharmacology Laboratory; School of Psychology, Faculty of Science, University of Sydney; NSW Australia

2. Discipline of Addiction Medicine, Faculty of Medicine; University of Sydney; NSW Australia

3. Drug and Alcohol Services, South East Sydney Local Health District, New South Wales Health; NSW Australia

4. National Cannabis Prevention and Information Centre; UNSW Medicine; Australia

5. Drug & Alcohol Clinical Services; Hunter New England Local Health District, New South Wales Ministry of Health; Australia

6. School of Medicine and Public Health, Faculty of Health, University of Newcastle; Australia

Funder

National Health and Medical Research Council

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference5 articles.

1. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial;Allsop;JAMA Psychiatry,2014

2. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 Study;Degenhardt;PLoS One,2013

3. The cannabis withdrawal scale development: patterns and predictors of cannabis withdrawal and distress;Allsop;Drug Alcohol Depend.,2011

4. Pharmacotherapies for cannabis dependence;Marshall;Cochrane Database Syst. Rev.,2014

5. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use;Schoedel;Hum. Psychopharmacol.,2011

Cited by 31 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. THC and CBD: Villain versus Hero? Insights into Adolescent Exposure;International Journal of Molecular Sciences;2023-03-09

2. A “Good” Smoke? The Off-Label Use of Cannabidiol to Reduce Cannabis Use;Frontiers in Psychiatry;2022-03-17

3. Cannabinoid Drugs in Mental Health Disorders;NeuroPsychopharmacotherapy;2022

4. ‘Synthetic cannabis’: A dangerous misnomer;International Journal of Drug Policy;2021-12

5. Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders;Frontiers in Pharmacology;2021-05-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3